Leaflet EMTRICITABINA/TENOFOVIR DISOPROXIL TILLOMED 200mg / 245mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: emtricitabine + tenofovir disoproxil (nucleoside/nucleotide reverse transcriptase inhibitor + antiretroviral)
ATC: J05AR03 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
This medicine may affect the kidneys.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
The combination of emtricitabine and tenofovir disoproxil is used for the treatment of HIV infection and for pre-exposure prophylaxis (PrEP). It works by inhibiting reverse transcriptase, preventing HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and decreased bone mineral density.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal function and bone density.
This medication is an effective option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.
General data about EMTRICITABINA/TENOFOVIR DISOPROXIL TILLOMED 200mg / 245mg
- Substance: emtricitabine + tenofovir disoproxil
- Date of latest medicines list: 01-06-2026
- Product code: W67377003
- Concentration: 200mg / 245mg
- Pharmaceutical form: film-coated tablets
- Quantity: 30
- Product type: Generic medicine
- Price: 380.73 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.